Eli Lilly pushes toward all-time highs: breakeven stop, next management window in 2 weeks

Eli Lilly is in week 4 of a buy signal, up 12.75% from entry with the stop already at breakeven — the position carries no residual loss risk. The healthcare sector is in a phase of strength and the stock ranks 51st among 145 US longs. A solid trade, but the price is hugging the all-time highs: a zone that calls for disciplined management, not chasing.